- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 10.03. | ImageneBio, Inc. GAAP EPS of -$9.64 | 1 | Seeking Alpha | ||
| 10.03. | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.02. | ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer | 1 | Investing.com | ||
| 10.02. | ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer | 986 | GlobeNewswire (Europe) | Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion... ► Artikel lesen | |
| 18.12.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | ImageneBio: Wedbush startet Coverage mit negativem Votum und Kursziel 2 US-Dollar | 2 | Investing.com Deutsch | ||
| 25.11.25 | Wedbush assumes coverage of ImageneBio stock with Underperform rating | 2 | Investing.com | ||
| 19.11.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc. GAAP EPS of -$2.91 | 1 | Seeking Alpha | ||
| 12.11.25 | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 486 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 12.11.25 | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.10.25 | ImageneBio ernennt CEO Kristin Yarema zur Interims-Finanzchefin | 2 | Investing.com Deutsch | ||
| 22.10.25 | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.10.25 | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.08.25 | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 227 | GlobeNewswire (Europe) | SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("ImageneBio"), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,676 | +4,61 % | EQS-News: Evotec SE: Evotec ernennt Dr. Ashiq H. Khan zum Chief Commercial Officer | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Dr. Ashiq H. Khan zum Chief Commercial Officer
01.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIOGEN | 153,40 | +1,29 % | Fetter Pharma-Deal: Aktie explodiert +135 % nach Übernahme - Biogen zahlt brutal drauf und fällt | © Foto: UnsplashBiogen greift tief in die Tasche. Während die Aktie der übernommenen Firma dreistellig explodiert, verliert die eigene Aktie - Zweifel am Deal bleiben.Biogen greift tief in die Tasche.... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,900 | -0,69 % | Where Will Viking Therapeutics Stock Be in 10 Years? | ||
| MAINZ BIOMED | 0,522 | +6,59 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 101,50 | +1,86 % | EQS-News: ABIVAX: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
01.04.2026 / 22:05 CET/CEST
The... ► Artikel lesen | |
| GALAPAGOS NV | 24,560 | -0,32 % | Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal | FOSTER CITY (dpa-AFX) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,800 | +4,09 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,394 | +3,26 % | Cardiff Oncology, Inc. - 8-K, Current Report | ||
| CYTOKINETICS | 57,22 | +1,31 % | Cytokinetics: Evercore ISI bestätigt "Outperform"-Rating im Vorfeld entscheidender Studiendaten | ||
| CYTOMX THERAPEUTICS | 3,877 | +4,67 % | CYTOMX THERAPEUTICS INC zeigt klare Stärke | ||
| COHERUS ONCOLOGY | 1,453 | +0,55 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 30,330 | -0,07 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| PERSONALIS | 5,490 | +3,98 % | Personalis, Inc.: Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing | Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate... ► Artikel lesen | |
| REGENXBIO | 7,970 | +5,06 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen |
Das Unternehmen IMAGENEBIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,750 Euro und damit +2,15 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.